Test Catalog

Lymphocytic Subpopulations

Code: CEL010

Type: Control de qualitat de medicaments de teràpia avançada Control de qualitat de teràpia cel•lular

Clinical information

Diagnostic Utility:

This test quantifies and determines the % of:

  • Viable leukocytes (cells viable positive for the CD45 membrane receptor)
  • Viable granulocytes/monocytes (cells viable positive for the CD416 membrane receptor)
  • Viable Natural Killer cells (cells viable positive for the CD56 membrane receptor)
  • B lymphocytes (cells viable positive for the CD19 membrane receptor)
  • T lymphocytes (cells viable positive for the CD3 membrane receptor)
  • Helper T lymphocytes (cells viable positive for the CD3 and CD4 membrane receptors)
  • Cytotoxic T lymphocytes (cells viable positive for the CD3 and CD8 membrane receptors)

Method: 

Flow cytometry.

Reference Values

The results are quantitative. The concentrations of leukocyte and lymphocyte subpopulations can vary greatly depending on the type of sample/product and whether they come from a healthy donor or a patient.

Diagnostic Algorithm:

Not applicable.

Response Time:

1 day.

Specimen information

Sample: Peripheral blood, umbilical cord blood, bone marrow, apheresis.
Tube: EDTA K3 tube (peripheral blood) or untreated tube (anticoagulated samples).
Minimum volume: 100 µL

Stability:

  • At room temperature: 1 day
  • In refrigeration: 1 day
  • Cryopreserved between -156oC and -196oC: 20 years

Transport instructions: Peripheral blood preferably at room temperature; umbilical cord blood, bone marrow, apheresis refrigerated.

Reason for rejection: Sample highly hemolyzed or with clots.

Administrative information

BST Code: CEL010
Test Description: Quantification and viability of CD3 and CD45 cells.
Synonyms: Not applicable
Section: Cellular Laboratory
BST Fee: Check the updated fees here.

Profiles:

Test CEL006 Quantification/viability of CD3 and CD45 can be requested alone. It is also performed within the following profiles:

References

K.Theilgaard-Mnch et al;  Flow cytometric assessment of lymphocyte subsets, lymphoidprogenitors, and hematopoietic stem cells in allogeneic stem cell grafts; Bone Marrow Transplantation, (2001) 28, 1073-1082.